What’s Your Diagnosis?
Localized Blistering Lesion in a Deployed Soldier
Mark W. Epps, PA-C, CPT, SP, USA and Gary E. Means, MD, MAJ, MC, USA
More
Geographic Access to VHA Rehabilitation Services for Traumatically Injured Veterans
Diane C. Cowper Ripley, PhD, Dean M. Reker, RN, PhD, Jeanne Hayes, PhD, W. Bruce Vogel, PhD, Samuel S. Wu, PhD, Rebecca J. Beyth, MD, Barbara J. Sigford, MD, Eric R. Litt, BA, and Xinping Wang, PhD
More
The Role of Rapid Response Systems
Detecting and Stabilizing Patients at Risk for Catastrophic Deterioration
Geoffrey K. Lighthall, MD, PhD and Shirley Paulson, RN, MPA
More
| CME Exam
Guest Editorial
Creating Home Away from Home: The Culture Transformation Movement in Long-Term Care
Jack Hooten, RN, MSN, MHA and Debra Shipman, RN, MSN, MBA
More
Practitioner Forum
Culture Transformation in Action: The Experience of One VA Community Living Center
You-Ying W. Whipple, MSS, Mick Magill, MSW, Cathy Decker, MSN, DeeAnn Koegel, BS, Danielle Keen, BS-HSA, and Marc Wooten, MD
More
| |
Drug Monitor
• Anticoagulation Safe for Some Elders, Not Others
• New Atypical Antipsychotic for Schizophrenia and Bipolar Disorder
More
Federal Health Matters
• OIG Finds VA Suicide Prevention Efforts Adequate
• VHA Facilities Improve Colonoscope Reprocessing Compliance
More
Reader Feedback
• Modify Clinical Reminders for Cancer Screening
More
Evolving Strategies for Chronic Idiopathic Thrombocytopenic Purpura in the VHA
It is estimated by experts that the incidence of chronic ITP in the population treated within the VHA is in equal or higher ratio to that in the public at large. For a variety of reasons, this incidence in the VHA may be expected to increase. The predicted five-year mortality rates for patients with ITP and persistently low platelet counts increase as patients age, leaving many in the VHA patient population at risk each year. Additionally, ITP can impede a variety of other diagnostic or medical treatments. While current treatment guidelines for ITP do exist, it is recognized that treatment options are not always optimal for the patient. Most current treatments for chronic ITP act by decreasing platelet destruction. None of the currently available agents work to improve platelet counts. Newly emerging treatment options may change these targets in treatment and hold hope for better long-term remissions for patients with ITP. This activity will explore ITP and its treatment options.This activity extends beyond a July 2009 CME webcast, which was planned and coordinated by the Annenberg Center for Health Sciences at Eisenhower. The webcast, its subsequent archive, and the enduring materials contained in this supplement were developed through the assistance of an unrestricted educational grant from GlaxoSmithKline. The supplement content is based on a discussion among the faculty members and was written by a writer from the Annenberg Center. Faculty have final editorial control for the piece. Successful completion of this activity is achieved by reading the material, reflecting on its implications in your practice, and completing the assessment component. The estimated time to complete the activity is 1 hour. This activity was originally released in October 2009 and is eligible for credit through September 30, 2010. The activity has been certified for physicians, pharmacists, nurse practitioners, and nurses. To obtain CE credit, please print a copy of the supplement and assessment materials, complete the Post-Test page (page 16) and the Activity Evaluation form (page 17), and return both pages, along with the completed Pre-Test (page 1), to the Annenberg Center for Health Sciences (ACHS #4655), 39000 Bob Hope Drive, Rancho Mirage, CA 92270 or fax to 760-773-4550.
More
|
